Back to Journals » Drug Design, Development and Therapy » Volume 4

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy

Authors Patel A, Moreland L

Published 1 October 2010 Volume 2010:4 Pages 263—278


Review by Single anonymous peer review

Peer reviewer comments 2

Aarat M Patel1,2, Larry W Moreland1
1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Pediatric Rheumatology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

Abstract: The dawn of the biologic era has been an exciting period for clinical research and patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, Actemra®), is a humanized monoclonal antibody against the interleukin 6 receptor and has been approved in many countries for the treatment of moderate to severe RA. There have been a number of important clinical trials demonstrating the efficacy of TCZ in active rheumatoid arthritis. This review summarizes the data on efficacy, patient-reported outcomes, adverse events, and safety from some of these trials. Current trends in clinical practice will be discussed. It is difficult to place TCZ and many new medications in the algorithm of treatment at present. However, the next few years will hopefully reveal their role as we better define abnormal immune processes in individuals with RA.

Keywords: tocilizumab, rheumatoid arthritis, interleukin-6, biologics

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.